Request Demo
Last update 19 Sep 2025
Dexrazoxane Hydrochloride
Last update 19 Sep 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms dexrazoxane, Topotect, Totect + [13] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 May 1995), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Australia) |
Login to view timeline
Structure/Sequence
Molecular FormulaC11H17ClN4O4 |
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N |
CAS Registry149003-01-0 |
Related
54
Clinical Trials associated with Dexrazoxane HydrochlorideNCT06647953
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
NCT06220032
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
NCT06262438
A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
100 Clinical Results associated with Dexrazoxane Hydrochloride
Login to view more data
100 Translational Medicine associated with Dexrazoxane Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dexrazoxane Hydrochloride
Login to view more data
1,044
Literatures (Medical) associated with Dexrazoxane Hydrochloride01 Dec 2025Natural Products and Bioprospecting
Design, synthesis and biological evaluation of buthutin derivatives as cardioprotective agents
Article
Author: Liu, Yu-Ming ; Wang, Li-Ning ; Gou, Xiang-Bo ; Yang, Shu-Han ; Hua, Xin-Hao ; Wang, Fa-Qi ; Xu, Yun-Sheng ; Liu, Yuan ; Shao, Chen-Yue
Abstract:
Natural products are the important sources in cardiovascular drug development. In this study, twenty-nine buthutin derivatives were designed, synthesized, and evaluated for their NHE-1 inhibition and protective effects on cardiomyocyte injury. The structure of the newly synthesized compounds had been confirmed by 1H-NMR, 13C-NMR, and HR-ESI-MS spectra. Among all target compounds at 1 μM, compounds 9d, 9f, 9k, 9m, and 9n, with a protection ratio exceeding 30%, exerted stronger protective effects on H9c2 cardiomyocyte than positive control dexrazoxane and buthutin A. Meanwhile, compounds 9k, 9m, and 9o showed the significant NHE-1 inhibitory activities on H9c2 cardiomyocyte, all with a dpHi/min value less than 0.23. What is more, compounds 9k, 9m, 9o and buthutin A all exhibited the specificity on NHE-1 inhibition. Molecular modelling studies suggested the ability of compounds 9m and 9o to establish interactions with three hydrogen bonds to Asp267 and Glu346 of NHE-1, but also the ability with much lower CDOCKER energies than positive control cariporide and buthutin A. The structure–activity relationship (SAR) studies suggested that the presences of amide group, four-carbon linker, and para hydroxyl benzene ring were advantageous pharmacophores for above two pharmacological actions. This research would open new avenues for developing amide-guanidine-based cardioprotective agents.Graphical Abstract
01 Nov 2025BREAST CANCER RESEARCH AND TREATMENT
Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials
Review
Author: Miller, Kyle J ; Rahman, Muhammad Aziz ; Grace, Fergal ; Vacharanukrauh, Pinyadapat ; Alif, Sheikh M
Abstract:
Purpose:
This study aimed to systematically assess the efficacy of cardioprotective agents in preventing anthracycline-induced cardiotoxicity in patients with breast cancer using a comprehensive network meta-analysis (NMA).
Methods:
This study included patients with breast cancer undergoing anthracycline-based chemotherapy. Randomized controlled trials (RCTs) published before March 2020 were identified through systematic searches in MEDLINE, Cochrane CENTRAL, Web of Science, and CINAHL. The primary outcome was left ventricular ejection fraction (LVEF), assessed using cardiac magnetic resonance imaging, multigated radionuclide angiography, or echocardiography. The NMA integrated direct and indirect comparisons to estimate the relative effectiveness of pharmacological interventions.
Results:
The systematic review included 31 RCTs with 3,228 participants, whereas the NMA synthesized 25 effect sizes from 15 RCTs. Mineralocorticoid receptor antagonists (MRAs) [standardized mean difference (SMD): −1.78, 95% confidence interval (CI): −2.81 to −0.75] and trimetazidine (SMD: −1.12, 95%CI: −2.32 to −0.09) exhibited the most substantial cardioprotective effects. Dexrazoxane (SMD: −0.53, 95%CI: −1.90 to −0.02) and β-blockers (SMD: −0.34, 95%CI: −0.70 to 0.02) showed potential benefits, albeit with greater uncertainty. Direct comparisons showed that dexrazoxane was more effective than β-blockers (SMD: −1.25, 95%CI: −2.22 to −0.48), with mineralocorticoid receptor antagonists (MRAs) outperforming both. Despite heterogeneity and potential publication bias, mineralocorticoid receptor antagonists (MRAs) and trimetazidine consistently ranked as the most effective interventions. LVEF findings confirmed the cardioprotective benefits of β-blockers, ARBs, ACE inhibitors, and dexrazoxane.
Conclusions:
RCT evidence suggested that cardioprotective drugs effectively mitigate anthracycline-induced LVEF decline. However, the lack of direct head-to-head trials limits definitive conclusions on comparative efficacy, warranting trials in patients with lower baseline LVEF to optimize cardioprotective strategies.
01 Oct 2025BIOCHEMICAL PHARMACOLOGY
Herbacetin mitigates oxidative stress and ferroptosis to protect against doxorubicin-induced cardiotoxicity
Article
Author: Xin, Wenxu ; Sun, Ning ; Yang, Hai ; Huang, Shaohong ; Zhang, Ke ; Ye, Chao ; Heng, Xinyu
The chemotherapy agent doxorubicin (DOX) is significantly constrained in its clinical application due to its notable cardiotoxicity. Dexrazoxane is the only drug approved by the FDA for the prevention of DOX-induced carditoxicity; however, it may also diminish the sensitivity of cancer cells to DOX chemotherapy. Consequently, there is an urgent need for the development of safe and effective therapeutic agents to mitigate the cardiotoxic effects induced by DOX. In this study, C57BL/6J mice and H9C2 cardiomyocytes were employed to establish models of DOX-induced cardiotoxicity. We examined the effects of herbacetin on myocardial damage, cardiac function, oxidative stress, ferroptosis and the associated signaling pathways using a variety of experimental techniques. Our results demonstrated that herbacetin mitigated DOX-induced myocardial damage and cardiac dysfunction both in vivo and in vitro. Mechanistically, herbacetin inhibits oxidative stress and lipid peroxidation by directly binding to tyrosine 342 of acyl-CoA synthetase long-chain family member 4 (ACSL4). This interaction inhibits lipid peroxidation and ferroptosis, suggesting that herbacetin may serve as a promising ferroptosis inhibitor and therapeutic agent for diseases associated with ferroptosis. This study underscores the therapeutic potential of herbacetin in DOX-induced cardiotoxicity and highlights the importance of modulating ACSL4 activity and inhibiting lipid peroxidation in diseases associated with ferroptosis.
5
News (Medical) associated with Dexrazoxane Hydrochloride11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
100 Deals associated with Dexrazoxane Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07807 | Dexrazoxane Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extravasation of Diagnostic and Therapeutic Materials | European Union | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Iceland | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Liechtenstein | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Norway | 27 Jul 2006 | |
| Cytoprotective Agent | China | 29 May 2006 | |
| Cardiomyopathies | United States | 26 May 1995 | |
| Metastatic breast cancer | United States | 26 May 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Phase 3 | Denmark | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Germany | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Italy | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Netherlands | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Poland | 01 Apr 2002 | |
| Bronchitis | Phase 3 | Denmark | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 25 | (Dexrazoxane 100mg/m2) | qpirunsrjf = hugfgphufs zqkmktabeo (fxajxzgqtj, jyqupzstll - mbvwpvezkf) View more | - | 12 Jun 2025 | ||
(Dexrazoxane 200mg/m2) | qpirunsrjf = suzhnnlrjv zqkmktabeo (fxajxzgqtj, rdbhbekwlm - cjdcacisja) View more | ||||||
Not Applicable | 263 | rnzxaoubvq(gqwingfcfk) = ubdwffhhoh btywyezyvk (basqkrsvko ) View more | - | 03 Dec 2022 | |||
rnzxaoubvq(gqwingfcfk) = warbejtpbk btywyezyvk (basqkrsvko ) View more | |||||||
Not Applicable | - | 1,308 | yycggoqhwg(kxlufazjqx): HR = 1.07 (95% CI, 0.78 - 1.47) View more | - | 15 Feb 2022 | ||
Phase 2 | 46 | (Arm A: VACdxr With ImmTher) | qklmxbzhjl(wijwbabyer) = trpmusrdwz eqqgunzmhy (vewderquml, pnbaniwhge - yduzgoyufg) View more | - | 29 Jan 2020 | ||
(Arm B: VACdxr) | qklmxbzhjl(wijwbabyer) = avyuholvyu eqqgunzmhy (vewderquml, srysyffolg - qmlyzgjusk) View more | ||||||
Phase 1 | 1 | vrgpyblipj = jstivulzuu qfgcfwurlj (todbviyytv, lctidttvit - gtpgmpnias) View more | - | 19 Feb 2019 | |||
Not Applicable | 1,014 | tfrrfolvkl(sugtcdovvb) = bfblvlzgod nnowghpuom (byhcbqmjvx ) View more | Positive | 01 Jun 2018 | |||
tfrrfolvkl(sugtcdovvb) = zzaiiimrbm nnowghpuom (byhcbqmjvx ) View more | |||||||
Phase 1/2 | 2 | lsbhjzqbvt = dueiymlkvl hurlbqfbpb (nofbiycjfs, ooqssjptpa - dxvrdzpnmu) View more | - | 13 Mar 2015 | |||
Not Applicable | 7 | (Outpatient Chemotherapy) | ucqmgvyolb(zvyuupphyl) = hvidmcbhlu qoubzxvgny (mahkpxfcxv, bpoauozgqo - ptxktzbcsj) View more | - | 10 Sep 2014 | ||
Surgery+Dexrazoxane+Mesna+Leucovorin+Doxorubicin+ifosfamide+Gemcitabine+Sargramostim+Methotrexate+cisplatin (Additional Risk-Adapted Outpatient Chemotherapy) | ucqmgvyolb(zvyuupphyl) = tdsotvsizd qoubzxvgny (mahkpxfcxv, mxbaklunbv - fpugcknnmp) View more | ||||||
Phase 2 | 7 | neoadjuvant therapy+dexrazoxane hydrochloride+filgrastim+doxorubicin hydrochloride+ifosfamide+irinotecan hydrochloride | rjjbvqtvne = bwxmltbuwu uchywzhsdo (cyvbkbxtwf, yukygmtzsi - jcgqfsatzf) View more | - | 28 Aug 2014 | ||
Phase 1 | 24 | therapeutic conventional surgery+dexrazoxane hydrochloride+Mesna+etoposide+Leucovorin Calcium+zoledronic acid+filgrastim+doxorubicin hydrochloride+ifosfamide+Cisplatin+methotrexate (Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid) | lcnuytuesa = eakmtrelhh rqcfuexivj (gtuxcjdjmh, pmyjsmhnff - bvdqcfgfdf) View more | - | 04 Jul 2014 | ||
therapeutic conventional surgery+dexrazoxane hydrochloride+Mesna+etoposide+Leucovorin Calcium+zoledronic acid+filgrastim+doxorubicin hydrochloride+ifosfamide+Cisplatin+methotrexate (Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid) | lcnuytuesa = wmqjhzhrlq rqcfuexivj (gtuxcjdjmh, kgyqbywxdc - nsorpzskdq) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free